Skip to main content

Table 1 Clinical and pathological information of patients

From: miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2

Number ID Age (year) Tsize (mm) Lymph node metastasis Grade AJCC anatomic stage ER PR HER2 Subtype
1 1,595,476 35 30 0 3 2A N N N Triple negative
2 1,597,702 44 25 0 3 2A N N N Triple negative
3 1,613,380 39 25 0 3 2A N N N Triple negative
4 1,561,558 47 30 0 2 2A N N N Triple negative
5 1,593,213 71 30 0 1 2A N N N Triple negative
6 1,558,369 67 45 2 3 2B N N P Her2 overexpressing
7 1,562,676 46 22 0 3 2A N N P Her2 overexpressing
8 1,568,640 72 25 3 3 2B N N P Her2 overexpressing
9 1,538,312 73 15 0 2 1A P P N Luminal A
10 1,538,856 59 40 3 3 2B P P N Luminal A
11 1,540,806 54 30 1 2 2B P P N Luminal A
12 1,557,688 61 15 0 2 1A P P N Luminal A
13 1,563,656 43 30 1 3 2B P P N Luminal A
14 1,594,881 44 20 0 2 1A P P N Luminal A
15 1,558,066 49 15 0 2 1A P P N Luminal A
16 1,547,013 62 15 0 1 1A P P N Luminal A
17 1,551,621 49 20 0 2 2A P P N Luminal A
18 1,554,600 74 20 2 3 2B P P N Luminal A
19 1,540,752 48 20 1 2 2B P P P Luminal B
20 1,545,637 44 50 13 3 3C P P P Luminal B
21 1,589,813 35 18 1 2 2A P P N Luminal A
22 1,595,773 64 27 0 1 2A P P N Luminal A
23 1,595,546 47 30 13 3 4 P P P Luminal B
24 1,596,351 45 63 0 3 2B P P P Luminal B
25 1,608,794 39 25 0 3 2A P P N Luminal A
26 1,609,339 52 30 12 3 3C P P N Luminal A
27 1,612,095 67 20 3 2 2B P P N Luminal A
28 1,595,081 39 30 22 3 3C P P N Luminal A
  1. AJCC American Joint Committee on Cancer, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, N negative, P positive, PR progesterone receptor, Tsize tumor size